This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

The Association of G9a Protein and Outcome of Patients With Endometrial Cancer

This study has been completed.
Information provided by (Responsible Party):
Sheng-Mou Hsiao, Far Eastern Memorial Hospital Identifier:
First received: January 5, 2011
Last updated: September 25, 2012
Last verified: September 2012
Tumor invasion and metastasis are the major causes of cancer-related death. Some studies have found that histone methyltransferases, such as EZH2, specifically affect metastasis in breast, gastric and prostate cancer. The functional roles of other members of the HMT family such as G9a in cancer remain obscure. Therefore, the investigators will investigate whether G9a have a role in recurrence/metastasis of endometrial cancer.

Condition Intervention
Outcome of Endometrial Cancer Other: no drug

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science

Further study details as provided by Sheng-Mou Hsiao, Far Eastern Memorial Hospital:

Primary Outcome Measures:
  • The role of G9a protein in endometrial cancer [ Time Frame: overall survial, disease-free survival ]
    We will correlate the G9a protein and outcome of endometrial cancer

Enrollment: 97
Study Start Date: January 2011
Study Completion Date: September 2012
Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: endometrial cancer Other: no drug
The role of G9a protein in patients with endometrial cancer


Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • all cases with endometrial cancer underwent staging operation

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01271764

Department of Obstetrics and Gynecology, Far-Eastern Memorial Hospital
Banqiao, New Taipei, Taiwan, 22050
Sponsors and Collaborators
Far Eastern Memorial Hospital
  More Information

Responsible Party: Sheng-Mou Hsiao, Chief, Department of Obstetrics & Gynecology, Far Eastern Memorial Hospital Identifier: NCT01271764     History of Changes
Other Study ID Numbers: 099095-E
Study First Received: January 5, 2011
Last Updated: September 25, 2012

Additional relevant MeSH terms:
Endometrial Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Uterine Diseases
Genital Diseases, Female processed this record on September 18, 2017